Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Asthma
Interventions
Nebulized Budesonide, Nitric Oxide Analyzer
Drug · Device
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
4 Years to 6 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Coral Gables, Florida
Conditions
Asthma
Interventions
RNS60, Normal Saline, Budesonide
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Costa Mesa, California • Los Angeles, California • Riverside, California
Completed Not applicable Interventional Results available

Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE)

NCT00961233
Conditions
Eosinophilic Esophagitis
Interventions
inhaled/swallowed budesonide, viscous/swallowed budesonide
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Asthma
Interventions
Nebulized Budesonide, Usual care (albuterol with or without oral steroid)
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
1 Year to 8 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
2
States / cities
Bellevue, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Tempe, Arizona • Anaheim, California
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Asthma, Pediatric ALL
Interventions
budesonide, beclomethasone
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
Up to 18 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Not yet recruiting Phase 1Phase 2 Interventional

Nebulized Nasal Steroids

NCT07270302
Conditions
Chronic Rhinosinusitis
Interventions
nebulized budesonide via NasoNeb, budesonide lavage via NeilMed
Combination Product
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Wheezing, Reactive Airway Disease, Mild Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
4 Years to 8 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Conditions
Asthma
Interventions
Budesonide respules
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
12 Months to 36 Months
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Acute Respiratory Distress Syndrome
Interventions
Budesonide, Placebo, Nebulizer
Drug · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
30 Days to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 3 Interventional Results available

The Budesonide in Babies (BiB) Trial

NCT04545866
Conditions
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 48 Hours
Enrollment
642 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Conditions
Asthma
Interventions
pulmicort respules
Drug
Lead sponsor
Phoenix Children's Hospital
Other
Eligibility
2 Years to 8 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona